← Home / ImageneBio, Inc. (IMA)
Stock Analysis

ImageneBio, Inc. (IMA)

IMA
IMA · Healthcare • Biotechnology
5.43 -2.16%
Track IMA in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when IMA price is:
52W Range Position
10%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-08-26 21:16 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and structural levels before acting.
⚖️
Fundamentals
Moderate / Negative / Pressured / Strong
Price Structure
Vulnerable
Momentum
Neutral
×
Current Resistance
Below Resistance
Risk Level
Elevated
Analysis Scope
1Y Daily
Key Decision Levels
Hold Above
Structure remains valid above support.
5.32
Break Above
No reliable confirmation level is currently available.
Not available
🎯
Next Objective
No defined objective is currently available for the primary technical setup.
Not available
×
Thesis Break
No setup-specific invalidation level is currently defined.
Not available
Recent Company Events
SEC VERIFIED
Latest material filings
AUG
5
Financial Results
HIGH
ImageneBio Reports Second Quarter 2026 Financial Results
5, 2026 (GLOBE NEWSWIRE) — ImageneBio, Inc.
8-K Filing SEC EDGAR
JUL
23
Management / Board
MEDIUM
IMA board and management update
On July 20, 2026, ImageneBio, Inc., a Delaware corporation (the “Company”), based in part on the recommendation of Kristin Yarema, Ph.D., the Company’s Chief Executive Officer, appointed Yanina Grant-Huerta as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effect...
8-K Filing SEC EDGAR
JUN
26
Management / Board
MEDIUM
IMA board and management update
On June 22, 2026, Robert Lally, our Senior Vice President of Finance and Operations and principal accounting officer, provided notice of his resignation, effective July 22, 2026.
8-K Filing SEC EDGAR
What's Driving IMA?
• No active technical setup
Momentum is Neutral. No qualified technical setup is currently active.
◆ Business quality is mixed
Revenue growth is moderate. Profitability is negative. Cash generation is pressured. Balance-sheet quality is strong.
⚠️ Key risk remains
Below 5.32
Full Analysis Workspace
Technical Signal
No Active Technical Setup
No qualified technical setup is currently active.
RSI(14)
42.3
Price Chart
IMA — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-08-25
Spec
Speculative premium
Valuation is very demanding relative to current fundamentals; expectations are high.
Market Cap
$63.9M
Company size
EV
$-70.4M
Debt-adjusted value
P/B
0.4
Low book multiple
EV/Sales
214.0
Very high
P/FCF
-2.8
Not meaningful
FCF Yield
-36.31%
Cash return
Not financial advice
Business Lens
Financial context is mixed
Financial conditions require selective monitoring.
Revenue Growth
Moderate
Profitability
Negative
Cash Flow
Pressured
Balance Sheet
Strong
💵 Revenue
800,000
≈ Moderate
📈 Net Income
-10.18M
↘ Negative
🧮 EPS (Basic)
-0.63
↘ Negative
ImageneBio, Inc.
Healthcare • Biotechnology